Bile Acid and Estrogen Receptors in Colon Cancer

结肠癌中的胆汁酸和雌激素受体

基本信息

  • 批准号:
    7256901
  • 负责人:
  • 金额:
    $ 27.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-03 至 2010-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Colorectal cancer is the second most common cause of cancer death in the United States. High fat diets are an important risk factor for colon cancer; conversely, estrogens protect against colon carcinogenesis. The mechanisms underlying the detrimental actions of fatty diets and the beneficial effects of estrogens are unclear. However, one compelling hypothesis is that fatty diets contribute to carcinogenesis by increasing colonic concentrations of bile acids, which stimulate cell proliferation and act as tumor promoters. There is strong epidemiological and animal model data linking elevated bile acid concentrations to colorectal cancer. We propose a unifying hypothesis in which the pro-carcinogenic effects of bile acids and the anti- carcinogenic actions of estrogens are mediated through the bile acid receptor FXR and the estrogen receptor beta (ERbeta), respectively. Both receptors are members of the steroid/thyroid hormone receptor family of ligand-activated transcription factors and are abundantly expressed in colon. In the proposed model, activation of FXR induces expression of another nuclear receptor, termed SHP, which suppresses the anti- proliferative actions of ERbeta. In preliminary data, it is shown that activation of FXR causes hyperproliferation of the colonic mucosa and that this effect requires SHP. Notably, induction of SHP correlates with repression of ERbeta both in vitro and in vivo. In this proposal, the roles of FXR, SHP, and ERbeta in colon carcinogenesis will be studied. In Specific Aim 1, the roles of FXR and SHP in proliferation and colon carcinogenesis promoted by bile acids will be examined. In Specific Aim 2, the molecular mechanisms underlying the protective actions of estrogens in colon will be studied. In Specific Aim 3, the mechanism whereby bile acids repress ERbeta expression will be examined. These studies will provide important insights into the complex relationship between bile acids, estrogens, and colorectal carcinogenesis. Moreover, since both FXR and ERbeta can be regulated by small molecule ligands, these studies may reveal novel opportunities for treating and preventing colon cancer.
描述(由申请人提供):结直肠癌是美国癌症死亡的第二大常见原因。高脂肪饮食是结肠癌的一个重要危险因素;相反,雌激素可以防止结肠癌的发生。脂肪饮食的有害作用和雌激素的有益作用的机制尚不清楚。然而,一个令人信服的假设是,高脂肪饮食通过增加结肠中胆汁酸的浓度而促进癌变,胆汁酸刺激细胞增殖并作为肿瘤促进剂。有强有力的流行病学和动物模型数据将胆汁酸浓度升高与结直肠癌联系起来。我们提出了一个统一的假设,其中胆汁酸的促癌作用和雌激素的抗癌作用分别通过胆汁酸受体FXR和雌激素受体β(ER β)介导。这两种受体都是配体激活转录因子的类固醇/甲状腺激素受体家族的成员,并在结肠中大量表达。在所提出的模型中,FXR的活化诱导另一种称为SHP的核受体的表达,其抑制ER β的抗增殖作用。在初步数据中,它表明,FXR的激活导致结肠粘膜的过度增殖,这种效果需要SHP。值得注意的是,SHP的诱导与体外和体内ER β的抑制相关。在这项提议中,FXR,SHP和ER β在结肠癌发生中的作用将被研究。在具体目标1中,将检查FXR和SHP在胆汁酸促进的增殖和结肠癌发生中的作用。在具体目标2中,将研究雌激素在结肠中保护作用的分子机制。在具体目标3中,将检查胆汁酸抑制ER β表达的机制。这些研究将为胆汁酸、雌激素和结直肠癌发生之间的复杂关系提供重要的见解。此外,由于FXR和ER β都可以通过小分子配体调节,这些研究可能揭示治疗和预防结肠癌的新机会。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN A. KLIEWER其他文献

STEVEN A. KLIEWER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN A. KLIEWER', 18)}}的其他基金

Coordinate Regulation of an Alcohol Protective Response by the Liver-derived Hormone FGF21
肝源性激素 FGF21 协调调节酒精保护反应
  • 批准号:
    10029530
  • 财政年份:
    2020
  • 资助金额:
    $ 27.06万
  • 项目类别:
Coordinate Regulation of an Alcohol Protective Response by the Liver-derived Hormone FGF21
肝源性激素 FGF21 协调调节酒精保护反应
  • 批准号:
    10453571
  • 财政年份:
    2020
  • 资助金额:
    $ 27.06万
  • 项目类别:
Coordinate Regulation of an Alcohol Protective Response by the Liver-derived Hormone FGF21
肝源性激素 FGF21 协调调节酒精保护反应
  • 批准号:
    10674919
  • 财政年份:
    2020
  • 资助金额:
    $ 27.06万
  • 项目类别:
The PPARgamma-FGF21 Signaling Pathway: Its Role in Thiazolidinedione Drug Action
PPARgamma-FGF21 信号通路:其在噻唑烷二酮类药物作用中的作用
  • 批准号:
    8074147
  • 财政年份:
    2010
  • 资助金额:
    $ 27.06万
  • 项目类别:
Bile Acid and Estrogen Receptors in Colon Cancer
结肠癌中的胆汁酸和雌激素受体
  • 批准号:
    7627971
  • 财政年份:
    2006
  • 资助金额:
    $ 27.06万
  • 项目类别:
Bile Acid and Estrogen Receptors in Colon Cancer
结肠癌中的胆汁酸和雌激素受体
  • 批准号:
    7144636
  • 财政年份:
    2006
  • 资助金额:
    $ 27.06万
  • 项目类别:
Bile Acid and Estrogen Receptors in Colon Cancer
结肠癌中的胆汁酸和雌激素受体
  • 批准号:
    7431678
  • 财政年份:
    2006
  • 资助金额:
    $ 27.06万
  • 项目类别:
Regulation of Metabolism by the Hormone FGF15/19
激素 FGF15/19 对代谢的调节
  • 批准号:
    8247793
  • 财政年份:
    2004
  • 资助金额:
    $ 27.06万
  • 项目类别:
Protection of Intestine by the Bile Acid Receptor FXR
胆汁酸受体 FXR 对肠道的保护
  • 批准号:
    6758489
  • 财政年份:
    2004
  • 资助金额:
    $ 27.06万
  • 项目类别:
Protection of Intestine by the Bile Acid Receptor FXR
胆汁酸受体 FXR 对肠道的保护
  • 批准号:
    6850779
  • 财政年份:
    2004
  • 资助金额:
    $ 27.06万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 27.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了